Peptide therapy, decoded.
200+ clinical monographs, interactive dosing calculators, and community reviews — all PubMed-referenced and free to access.
Latest Research & Education
Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant antifibrotic activity in pulmonary fibrosis models by functioning as a PAR-1 antagonist that disrupts the coagulation factor Xa-PAR-1 signaling axis. The peptide inhibited fibroblast invasion and migration with a favorable safety profile—no adverse effects at 0.5 mg/kg/day and only mild hepatomegaly at supratherapeutic doses.
Peptide Half-Life Explained: Why Timing Your Doses Actually Matters
Peptide half-life determines how long a peptide stays active in your body and directly dictates dosing frequency. From BPC-157's 4-hour half-life to semaglutide's 7-day persistence, understanding pharmacokinetics helps optimize results and minimize side effects.
Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review
A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, finding selective cytotoxicity against tumor cells via membrane disruption and apoptosis induction, though clinical evidence remains limited to early-phase trials.
Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial
The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing significant MASH resolution without worsening fibrosis at 24 weeks. FDA granted Breakthrough Therapy designation in January 2026.
Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial
Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight reduction at 68 weeks in the pivotal TRIUMPH-4 trial — the largest weight loss ever reported for any anti-obesity medication in Phase 3.
Oral vs Injectable Peptides: Bioavailability and Effectiveness Compared
Injectable peptides deliver 65-100% bioavailability while oral peptides typically achieve under 1-2%, making injection the gold standard for most peptide therapies. Oral semaglutide with SNAC technology is the notable exception, reaching ~1% bioavailability — enough for clinical efficacy at higher doses.
Real Experiences from Real UsersNEW
Game-changer for my knee recovery
After 6 weeks of subcutaneous injections, the chronic tendon pain I'd had for 2 years was down to almost nothing. Combined with PT, the results were remarkable.
Verified user · 8 weeks
Steady weight loss, minimal sides
Lost 14 lbs over 3 months on the titration schedule. Nausea was real the first 2 weeks but manageable. Worth it for the appetite control alone.
Verified user · 12 weeks
Best GH stack I've tried
Noticeably better sleep by week 2, improved recovery from training by week 4. Skin quality improved. No water retention like with GHRP-6.
Verified user · 16 weeks
Monographs
Interactive Tools
Languages
Independent
掌握最新動態
臨床更新、產業新聞、新研究摘要和工具發佈通知。
我們尊重你的隱私。可隨時取消訂閱。